0.07  0 (0%)		12-07 15:58
Open: 0.0675 High: 0.07 Volume: 95,808		Pre. Close: 0.07 Low: 0.065 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	0.03	1-year :	0.04
Resists	First :	0.02	Second :	0.03
Pivot price	0.01
Supports	First :	0.01	Second :	0.01
MAs	MA(5) :	0.01	MA(20) :	0.01
	MA(100) :	0.03	MA(250) :	0.24
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	7	D(3) :	8.7
RSI	RSI(14): 39.5
52-week	High :	1.57	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EVFM ] has closed above bottom band by 17.7%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.01 - 0.01	0.01 - 0.01
Close:	0.02 - 0.02	0.02 - 0.02

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Tue, 14 Nov 2023
2023-11-14 | OTCQB:EVFM | Press Release | Evofem Biosciences Inc - Stockhouse Publishing

Tue, 24 Oct 2023
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023 - Yahoo Finance

Wed, 27 Sep 2023
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi ... - PR Newswire

Mon, 11 Sep 2023
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor - PR Newswire

Tue, 22 Aug 2023
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange - Yahoo Finance

Mon, 14 Aug 2023
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023 - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	216 (M)
Shares Float	0 (M)
Held by Insiders	0.1 (%)
Held by Institutions	4.4 (%)
Shares Short	8,680 (K)
Shares Short P.Month	17,820 (K)

EPS	-1.4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.76
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.05
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.02
PEG Ratio	0
Price to Book value	-0.03
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	2018-01-17
Ex-Dividend Date	Invalid DateTime.